KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Castle Biosciences (CSTL) Accumulated Depreciation & Amortization (2018 - 2026)

Castle Biosciences' Accumulated Depreciation & Amortization history spans 8 years, with the latest figure at $18.3 million for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 42.58% to $18.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $18.3 million, a 42.58% increase, with the full-year FY2025 number at $18.3 million, up 42.58% from a year prior.
  • Accumulated Depreciation & Amortization hit $18.3 million in Q4 2025 for Castle Biosciences, up from $16.8 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for CSTL hit a ceiling of $18.3 million in Q4 2025 and a floor of $867000.0 in Q2 2021.
  • Historically, Accumulated Depreciation & Amortization has averaged $8.4 million across 5 years, with a median of $7.6 million in 2022.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: skyrocketed 670.47% in 2022 and later dropped 5.81% in 2023.
  • Tracing CSTL's Accumulated Depreciation & Amortization over 5 years: stood at $3.0 million in 2021, then soared by 157.99% to $7.8 million in 2022, then increased by 3.35% to $8.1 million in 2023, then surged by 58.22% to $12.8 million in 2024, then skyrocketed by 42.58% to $18.3 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for CSTL at $18.3 million in Q4 2025, $16.8 million in Q3 2025, and $15.5 million in Q2 2025.